Doraya is an innovative catheter device for treating patients resistant to diuretics with Acute Heart Failure (AHF) condition.

Project Information

Doraya

Grant agreement ID: 855362

DOI

10.3030/855362

Project closed

EC signature date 31 January 2019

Start date 1 January 2019

End date 30 April 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

REVAMP MEDICAL LTD
Israel

Periodic Reporting for period 1 - Doraya (Doraya is an innovative catheter device for treating patients resistant to diuretics with Acute Heart Failure (AHF) condition.)

Reporting period: 2019-01-01 to 2019-04-30

Summary of the context and overall objectives of the project

Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure (HF), which typically includes difficulty in breathing, leg or feet swelling, and fatigue. HF is a growing global problem, affecting millions of people around the world, and more than 6M people in Europe. AHF is normally associated with severe congestion of multiple organs by fluid that is inadequately circulated by the failing heart.
Fluid decongestion is the key treatment of AHF, and AHF patients are treated with diuretics. Diuretics are a family of drugs designed to increase urine output, thus removing excess fluids and attempting to dry the patient. However, 20-30% of AHF admitted patients suffer from poor response to diuretics, preventing their proper and rapid fluid removal. Because currently there are no viable therapies for these patients, they have increased mortality, longer and costly hospital stays, and higher re-admission rates.
To solve these problems, Revamp Medical has developed Doraya™, an innovative catheter-based device designed for AHF patients who suffer from poor response to diuretics. Doraya™ helps to relieve fluid congestion by improving diuretic efficiency. This temporary catheter will expedite treatment by offering cardiologists a completely new approach to manage their admitted patients.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During Phase 1, Revamp produced a work plan, detailing the main technical steps to make Doraya™ ready for market. Also during the Feasibility Study, the business viability has been evaluated by means of a detailed market analysis (size, barriers, customer segments, and competitors) and preparing a commercialisation strategy and a detailed financial analysis to understand the expected financial performance. The results achieved during the project, confirming Doraya™'s expected performance by all stakeholders, will be communicated through a series of channels (online, events such as conferences, and publications).

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Revamp Medical, founded in 2016, is an Israeli-based medical device start-up company in the cardiovascular field. Revamp's goal is to resolve one of the most urgent unmet needs in AHF patients. Revamp is set to deliver an easily adoptable solution using a patented temporary catheter, the Doraya™. Doraya™ will provide quick treatment for AHF patients who do not respond to diuretics, reducing hospitalization duration and readmission (which will reduce costs by a 50%), and reducing mortality rates. The SME Instrument project fits into Revamp's overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of Doraya™ and its market uptake.

Benefits of using Doraya™ to treat AHF patients resistant to diuretics.